Sunil Healthcare's Stock Reaches 52-Week High, Outperforms Sector and Sensex
Sunil Healthcare, a microcap pharmaceutical company, has reached a 52-week high of Rs.93.12 on April 30, 2024. Despite a 'Sell' rating from MarketsMojo, the stock has outperformed the sector by 4.56% and has seen a 55.07% increase in value in the past 9 days. It opened today with a gain of 4.99% and has maintained its high value throughout the day. Sunil Healthcare is also trading above its moving averages and has shown a remarkable 1-year performance of 41.31%, indicating its potential for growth in the future.
Sunil Healthcare, a microcap pharmaceutical company, has been making headlines in the stock market recently. On April 30, 2024, the company's stock price reached a 52-week high of Rs.93.12, which is a significant milestone for the company.
According to MarketsMOJO, a leading stock market analysis platform, the current stock call for Sunil Healthcare is 'Sell'. However, the company's recent performance has been impressive, with the stock outperforming the sector by 4.56%. In fact, the stock has been on a winning streak for the past 9 days, with a remarkable 55.07% increase in its value during this period.
The stock opened today with a gain of 4.99%, which is a positive sign for investors. The day's high for Sunil Healthcare was Rs.93.12, which is also the current trading price. This indicates that the stock has maintained its high value throughout the day, with no significant fluctuations.
In terms of moving averages, Sunil Healthcare is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This is a strong indication of the company's consistent performance and positive market sentiment.
When compared to the Sensex, Sunil Healthcare has shown a remarkable 1-year performance of 41.31%, while the Sensex has only recorded a 22.39% increase. This further highlights the company's strong performance and potential for growth in the future.
Overall, Sunil Healthcare's recent 52-week high and consistent performance in the stock market make it a company to watch out for in the pharmaceutical industry. With its strong financials and positive market sentiment, the company is poised for further growth and success in the coming years.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
